Clinical Trials List
2022-05-01 - 2025-12-31
Phase II
Recruiting5
ICD-10C56.1
Malignant neoplasm of right ovary
ICD-10C56.2
Malignant neoplasm of left ovary
ICD-10C56.9
Malignant neoplasm of unspecified ovary
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9183.0
Malignant neoplasm of ovary
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- YING-CHENG CHIANG Division of Obstetrics & Gynecology
- 郭冠廷 Division of Others
- Wen-Fang Cheng Division of Obstetrics & Gynecology
- 陳宇立 Division of Obstetrics & Gynecology
- 童寶玲 Division of Obstetrics & Gynecology
- 戴依柔 Division of Obstetrics & Gynecology
- 施怡倫 Division of Radiology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 鄭雅敏 Division of Obstetrics & Gynecology
- Keng-Fu Hsu Division of Obstetrics & Gynecology
- Cheng-Yang Chou Division of Obstetrics & Gynecology
- 吳珮瑩 Division of Obstetrics & Gynecology
- Meng-Ru Shen Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 簡宏如 Division of Obstetrics & Gynecology
- 林岳民 Division of Others
- 曾若涵 Division of Hematology & Oncology
- 林炫聿 Division of Hematology & Oncology
- Chien-Hsun Li Division of Others -
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
12 participants
-
Global
160 participants
